Outcome of second- and third-line Helicobacter pylori eradication therapies based on antimicrobial susceptibility testing (Q41070434)

26 September 2017

Outcome of second- and third-line Helicobacter pylori eradication therapies based on antimicrobial susceptibility testing (English)

1 reference

eradication of infectious diseases

26 September 2017

0 references

1 reference

Sarah Draeger

1

1 reference

26 September 2017

Nicole Wüppenhorst

series ordinal

2

1 reference

26 September 2017

Manfred Kist

series ordinal

3

1 reference

26 September 2017

Erik-Oliver Glocker

series ordinal

4

1 reference

26 September 2017

language of work or name

English

0 references

publication date

5 August 2015

1 reference

Journal of Antimicrobial Chemotherapy

26 September 2017

1 reference

26 September 2017

70

1 reference

26 September 2017

11

1 reference

26 September 2017

3141-3145

1 reference

Helicobacter pylori in health and disease

26 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

High secondary resistance to quinolones in German Helicobacter pylori clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Helicobacter pylori treatment in the era of increasing antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Practical treatment of Helicobacter pylori: a balanced view in changing times

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Improving compliance with helicobacter pylori eradication therapy: when and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

CYP2C19 polymorphism and proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV223

21 January 2018

Identifiers

DOI

10.1093/JAC/DKV223

1 reference

26 September 2017

1 reference